A., & Kaasinen, E
Ahmed AS, Sheng MH, Wasnik S, Baylink DJ, Lau KW
The clinical efficacy of ALC and NAC has been evaluated in several trials [167, 172, 176, 199, 210, 237], the preliminary encouraging data and physiopathological frameworks support the need to study these compounds in this context and clarify their role [23, 24, 28, 199]
These medications seem to reduce the risk of progression to ESKD by targeting pro-inflammatory pathways, she explained during her presentation
*Correspondence: Vishwanath Venketaraman, [email protected] This article was submitted to Clinical Microbiology, a section of the journal Frontiers in Cellular and Infection Microbiology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
When delivered within a medical framework, IV infusion therapy is generally well tolerated